The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Alhemo prophylaxis is linked to better quality of life and a lower treatment burden for hemophilia patients without ...

The FDA approved fitusiran (Qfitlia, Sanofi) for routine prophylaxis for prevention or reduction in bleeding episodes in ...

Platelet spreading and clot contraction are controlled by different pathways. This discovery leads to safer treatments for ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.